Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $1,201,390.62 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. This represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Kirn also recently made the following trade(s):

• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Stock Down 0.9%

NASDAQ FDMT opened at $11.52 on Friday. 4D Molecular Therapeutics, Inc. has a twelve month low of $3.68 and a twelve month high of $12.34. The business has a 50-day moving average price of $9.54 and a 200-day moving average price of $9.14. The firm has a market cap of $602.27 million, a price-to-earnings ratio of -4.48 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. Research analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $39,000. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the third quarter valued at approximately $41,000. AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Daiwa Securities Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the period. Finally, Rangeley Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the second quarter worth approximately $48,000. Institutional investors own 99.27% of the company’s stock.

Wall Street Analysts Forecast Growth

FDMT has been the topic of several research analyst reports. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Chardan Capital reissued a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Finally, Royal Bank Of Canada raised their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.